Emerging Targets for the Diagnosis of Cancer

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

An Introduction to NTRK

TRK Protein Expression in Normal Tissues

Timeline of Fusion Discoveries

NTRK Fusions

NTRK Rearrangements Common in Rare Neoplasms

Occurrence of NTRK Fusions Across Cancer Types

NTRK Testing Presents Challenges to Clinicians

NTRK IHC

Pan-TRK IHC -- Selected Studies Hechtman et al, Am J Surg Pathol, 2017

Pan-TRK IHC -- Selected Studies Hung et al, Histopathology, 2018

FISH for NTRK1/2/3

Diversity of NTRK1/2/3 Fusion Partners

NTRK1/2/3 Testing DNA-Based NGS

RNA-Based NGS Testing

Anchored Multiplex PCR: NTRK Fusion Detected by Archer®

DNA-NGS and RNA-NGS Are Complementary

Other Methods

Different Assays for NTRK Assessment Advantages and Disadvantages

TRK Inhibitors Are Highly Effective in NTRK Fusion-Positive Cancers

Larotrectinib in NTRK Fusion-Positive Cancers

Larotrectinib Efficacy Across Tumor Type

Durability of Response

Entrectinib in NTRK Fusion-Positive Cancers

Entrectinib ORR by Tumor Type

DoR, PFS, and OS With Entrectinib

Intracranial ORR With Entrectinib

Select TRAEs With Larotrectinib

Select TRAEs With Entrectinib

On-Target Resistance to First-Generation TRK Inhibitors

Overcoming TRK TKI Resistance With Second-Generation TRK Inhibitors

Selecting Appropriate Patients for TRK Inhibitors

Best Practices for Communicating Test Results Know Your Audience

Best Practices for Communicating Test Results CAP Checklist

Abbreviations

Abbreviations (cont)

Abbreviations (cont)